Abstract In this study, a specific antibody against butyrylcholinesterase (BuChE) bound to organophosphate (OP) nerve agents was developed to be used in enzymelinked immunosorbent assays (ELISA). OP nerve agents such as sarin, soman, and VX are known to act on the neuromuscular junctions and were synthesized at the Armed Force Chemical, Biological, and Radiological Defense Command in Republic of Korea and studied after confirming inactivation of BuChE. Each inactivated OP-BuChE (OPiBuChE) was used as the antigen for developing monoclonal antibodies (mAbs) in mice for detection of OP bound BuChE. The fusion was performed after immunization and then hybridoma cells for the antibodies were generated. As a result, the partial specific antibody against soman-iBuChE was confirmed via ELISA. Thus, the antibody may recognize three-dimensional structure of OP-iBuChE that is changed upon soman and BuChE reaction, not an OP binding pocket of BuChE. Furthermore, this partial specific monoclonal antibody may be used in a competitive ELISA to detect the soman-iBuChE. Taken together, we suggest that the antibody could be applied to evaluate the soman presence in blood, serum, and urine.
Introduction
Nerve agents (NAs) including many organophosphate (OP) pesticides continue to pose a health risk and significant global security concern of terrorism. NAs are alkylphosphonic acid esters. Sarin and soman are methylphosphonofluoridate containing a fluorine substituent group. VX is an alkylphosphonothiolate containing sulfur group. These NAs have a unique C-P bond that is not found in OP pesticides and is very hydrolysis resistant. Moreover, binding reactions of NAs to esterases such as acetylcholinesterase (AChE), cholinesterase (ChE), carboxylesterases (CarbE), and other proteins occur by hydrolysis. Both OP pesticides and NAs lose their acyl radicals after their reaction with the esterase [1] . As OP nerve agents enter blood, they cause over stimulation of the cholinergic nervous system, paralysis, and ultimately death by inactivation of acetylcholinesterases (AChE) and butyrylcholinesterases (BuChE) critical to the central nervous system [2, 3] . In other words, AChE and BuChE inactivates the neurotransmitter acetylcholine (Ach) and is hence viable therapeutic targets in OP nerve agents, which is characterized by a cholinergic toxidrome.
OP nerve agents in air first covalently bind BuChE that is present in large quantities in plasma, even though AChE is 1.5 * 4 times higher in affinity to OP than BuChE [4] .
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Moreover, the diagnostic test using AChE is out of detection range for OP because there is a very low amount of AChE in plasma. Therefore, it is useful to analyze BuChE covalently bound to OP nerve agents to know the kind of nerve agents. Furthermore, Manoharan et al. reported that BuChE was about 700 times higher in activity than AChE in plasma when the result of comparison with esterase activity of BuChE and AChE was 5.6 ± 1.2 and 0.008 ± 0.001 U/g, respectively [5] . In general, plasma of adult human is about 3500 g, total BuChE units in plasma are 19,600 (about 196 nmol), and total AChE units in plasma is 20 (about 0.05 nmol). Finally, BuChE is 4000 times more than AChE in plasma and is superior to detect the infiltration and contamination of OP nerve agents in blood. After NAs bind to AChE and BuChE, there is a non-enzymatic time-dependent intramolecular rearrangement which leads to loss of one alkyl group bound to the phosphorus, known as ''aging reaction'' which means the time between NA exposure and irreversible phosphonylation [3] . Phosphonylated AChE and BuChE may be subject to be spontaneously changed dealkylation (aging) and dephosphonylation (reactivation) [6] . Herein, aging proceeds through P-O bond scission and this acid-catalyzed process results in formation of a negatively charged phosphonyl-cholinesterase adduct [7, 8] . Thus, early diagnosis of OP nerve agent exposure is essential to do therapy prior to onset of life threatening signs.
Therefore, use of OP-BuChE as a biomarker to detect exposure to nerve agents, there are several advantages as follows: (1) BuChE is present in large quantities in human plasma and tissue that is easy to obtain, (2) BuChE reacts rapidly with low doses of OP esters, (3) OP makes an irreversible covalent bond with BuChE, and it is stable in the circulation as well as in stored plasma [9] , (4) the halflife of BuChE is 12 days in the circulation; it means that blood can be drawn several days after an incident to detect OP-BuChE adducts [10] , (5) methods to extract BuChE from plasma in a single step by binding to immobilized monoclonal antibody have been developed [11] , (6) digestion of BuChE with pepsin yields the active sitecontaining peptide modified on Ser198 by OP. A smallsized peptide has an advantage in mass spectral analysis where small peptides ionize more readily than large peptides [11, 12] , and (7) mass spectrometry methods have been developed by the TNO laboratory in Rijswijk and adopted worldwide to diagnose OP exposure by analyzing OP adducts on BuChE [11] .
Most research on diagnostic methods of NA exposure has been directed at the most available samples of exposed person such as the exposed blood (serum, plasma, whole blood, or red cells) and urine. Intact NAs are available in the organism for a few hours; therefore, blood sampling should be obtained within a few hours after OP exposure. Thus, intact agents do not seem to be a good target of retrospective detection of exposure [13] [14] [15] . There are about four approaches to detect exposure to NAs: AChE activity measurement, determination of OP hydrolysis products in plasma and urine, fluoride reactivation of phosphonylated binding sites, and mass spectrometric determination of cholinesterase adducts [3] . Of the approaches listed above, the colorimetric assay lacks sensitivity and specificity, while gas chromatography/tandem mass spectrophotometer (GC/MS-MS) methods are currently limited to laboratory analyses, are time-consuming, and require highly trained personnel. Therefore, rapid, sensitive, and field-deployable methods are still needed. In other words, new or improved diagnostic techniques or tools can provide rapid and reliable evaluation of OP-agent exposure, and will enhance our ability to respond quickly to an emergency and thus will improve our medical capability against OP exposure. Recently, immunochromatographic test strips using anti-OP-HSA antibody against OP-HSA peptide [16] and anti-AChE antibody against AChE [17] have been developed as a rapid diagnostic test kit. However, these antibodies as detection reagents of OP have low sensitivity and specificity because they are not the antibodies specific enough to recognize specific binding sites between OP and HSA or OP and AChE. Based on these findings, we present the first report on development of the monoclonal antibody recognizing the three-dimensional structure of inactivated soman-BuChE adduct for detection of soman in intoxicated persons. In this study, the monoclonal antibody recognizing the three dimensionally changed structure of BuChE by soman was developed. This monoclonal antibody can be used for diagnosis the soman contaminated person more rapidly and easily.
Materials and Methods

Synthesis of organophosphate nerve agents
Human butyrylcholinesterase (BuChE) was purchased from Mybiosource, Inc (San Diego, CA, USA). BuChE was dissolved in phosphate buffered saline (PBS) at pH 7.4 containing 0.02% of sodium azide(NaN 3 ). Organophosphate (OP) nerve agents (NAs) were synthesized and approved for binding out from the Armed Force Chemical, Biological, and Radiological (CBR) Defense Command in Republic of Korea. The NAs were dissolved in PBS at pH 7.4 to make 2.2 mM solutions and used immediately.
Preparation of organophosphatebutyrylcholinesterase adducts
To make OP-BuChE adduct, 1.68 mL of BuChE (49.4 nmole) in PBS (pH 7.4) was reacted with 0.84 mL organophosphate nerve agents (2.2 lmol) at 25°C for 4 or 24 h. BuChE and NAs were mixed at 1:45 molar ratio to produce OP-BuChE adducts. The molar ratio is enough to achieve 100% inactivation of BuChE.
Measurement of butyrylcholinesterase enzymatic activities
The enzymatic activity of OP-iBuChE mixture was measured using the Ellman's method [18, 19] . Briefly, 0.5 ll of the OP and BuChE mixture was treated with 0.5 mM 5,5-dithiobis (2-nitrobenzoic acid) (DTNB) and 1 mM butyrylthiocholine (Sigma-Aldrich, MI, USA) in 1 mL of 0.1 M potassium phosphate buffer at pH 7.0 for 10 min at room temperature (RT). The inactivation was measured by absorbance of the mixture at 412 nm wavelength using the Spectra Max M5 microplates reader (Molecular Device, LLC., CA, USA). To measure the inhibitory proportion of iBuChE conjugated to nerve agents, the free nerve agents, not conjugated to BuChE, were eliminated by using molecular weight cutoff centrifugal filter (10 kDa cutoff) and centrifuged for 5 min at 10,000 rpm, 4°C, total six times. The residual OP in the filtrated solution was measured and assayed by GC/MS-MS.
Preparation of hybridoma cells producing monoclonal antibody
Six-wk-old female BALB/C mice were included in the study, and four female BALB/c mice were immunized with BuChE containing aluminum chloride and incomplete Freund's adjuvants at a dosage of 20 lg protein per mouse through footpad manner. After 2 weeks, serum was collected from four mice and then antibody titer was measured with ELISA. After antibody titration, the mice were boosted with the same protein dose every 2 weeks. If the serum antibody titer is over 1.5 OD at 1:1000 dilution as a result of ELISA, the mouse was killed and splenocytes were isolated. The cells were fused with Sp2/0-Ag14 myeloma cells using polyethylene glycol. The fused cells were selected and proliferated in HAT medium to eliminate unfused cells. The selected fused cells were transferred in DEME medium. The hybridoma cells producing monoclonal antibodies (mAbs) were subcloned through the limiting dilution method followed by direct ELISA measurement.
Screening of monoclonal antibody against BuChE and OP-iBuChE using ELISA The plates were incubated with 100 ll of coating buffer (0.2 M sodium carbonated, pH 9.2) overnight at 4°C. After three washes of 0.015 M PBS with 0.1% tween 20, 100 ng of BuChE in 100 ll was used to coat each well for 2 h at room temperature. After washing, the plates were blocked with 200 ll of blocking buffer (0.015 M PBS containing 0.1% tween 20, 0.5% Bovine serum albumin) for 1 h. For screening of monoclonal antibodies, the supernatant from each clone of hybridoma cells was incubated for 2 h at room temperature. After washing as above, 100 ll of diluted goat anti-mouse IgG-HRP conjugate antibody was added for 1 h at room temperature. After washing as described, 100 ll of TMB substrate was added, and incubated for 7 min at RT. The reaction was stopped using equal volume of 2 N H 2 SO 4 . Then the absorbance of reactant was measured using UV spectrophotometer at 450 nm.
Purification of monoclonal antibody from hybridoma supernatant
The hybridoma cells were cultured in a tissue culture plates with DMEM containing 10% FBS and 1:100 penicillin/ streptomycin, and then, the culture medium was replaced to a serum-free DMEM. The cultured hybridoma was collected and centrifuged at 2500 rpm for 5 min, 4°C. After collected supernatant was filtered with the 0.22 lm filter top, supernatant was applied to equilibrated protein A agarose column at 4°C. After washing, antibodies were eluted with 100 mM glycine, pH 2.5, and then neutralized with 1 M Tris, pH 9.5. The obtained fractions were dialyzed in PBS overnight, and the antibody concentrations were measured.
Results
In this study, we demonstrated the detection of inactivated BuChE mediated by OP nerve agents using monoclonal antibodies. To evaluate the binding between iBuChE and OPs, we modeled the structures of BuChE binding nerve agents including sarin, soman, or VX.
Before immunization for production of mAbs against OP-iBuChE, the binding site between BuChE and OPs were investigated by using 3D molecular docking and virtual screening program (AutoDockVina). As shown in Fig. 1 , the structure of the human BuChE active site gorge is schematized [20] . The toxic mechanism of OP is based on the interaction and irreversible inhibition of BuChE by phosphorylation and phosphonylation of the active site Ser198 [21, 22] . The comparison of aged and non-aged forms of BuChE is shown in Fig. 2A and yellow and purple structures indicate non-aged form and aged form, respectively. These structures have a little difference at 0.215 angstroms (Å ) RMSD (root mean square deviation). Therefore, it may be difficult to produce specific mAbs to Appl Biol Chem (2017) 60(3):233-240 235 be able to distinguish aged form from non-aged form due to little difference of 3D model for two structures. Figure 2B is magnified from red circle of Fig. 2A and shows the binding site for OP nerve agents. The prediction image in Fig. 2C shows binding between Ser198 and OP through aging pathway and the red circle indicates the phosphorylation between OP and BuChE residue Ser198. Herein, the prediction image for binding Ser198 and OP was drawn with PBD ID 1p0i of non-aged form among the known BuChE structures. As shown in Fig. 2D -G, these dimensional structures represent binding and phosphorylation of inactivated sarin-BuChE, soman-BuChE, VX-BuChE, and diazinon-BuChE, respectively. OP nerve agents such as sarin, soman, and VX were synthesized in the Armed Force CBR Defense Command in Republic of Korea. In order to determine the purity and amount of the synthesized OP nerve agents including sarin, soman, and VX, the synthesized OPs were measured using GC/MS-MS and the chromatograms are shown in Fig. 3 . The purity of the synthesized OPs was determined to be 97.8% for sarin, 99.5% for soman, and 62.6% for VX, and their concentrations were 41.2, 55.2, and 86.3 mg, respectively (Table 1) . Although lower purity (62.6%) for nerve agent VX indicated its impaired structure, actually the VX inactivated the enzymatic activities of human BuChE (data not shown).
The OP nerve agents react with BuChE in plasma. The reactants inhibit the enzymatic activities of BuChE. The inactivation of BuChE by sarin, soman, and VX was measured by Ellman's assay [18, 19] . Active BuChE was diluted in twofold series and used as the criteria of standard activation. The inactivation of BuChE was measured when the value of BuChE by OP is over 0.99. After the 4-hour reaction, BuChE retains 0.9% activity. In the 24-hour reaction, BuChE was completely inactivated (data not shown). Therefore, all experiments were performed after the complete inactivation of the OPs. Moreover, OP nerve agents were mostly toxic compounds in mammals and insects. Hence, it is important that OP nerve agent must be eliminated to make specific antibodies using animal model from the reaction solutions. To remove the residual of OP nerve agents, the reacted solution was filtrated by molecular weight cutoff filter. After that, the concentration of free OP nerve agents was confirmed using GC/MS-MS whether the residual of OP nerve agents exists or not. As shown in Table 1 , the residuals of sarin, soman, and VX were confirmed to be under 1 part per billion (ppb), 1 and 100 ppb, respectively. Although free OP nerve agents were not completely eliminated from reaction compared with the standard, the OP nerve agents were injected to mice at 0.1 ng/ll with the injection volume under LD 50 without clinical symptom. As a result, the amount of native BuChE, sarin-iBuChE, soman-iBuChE, and VX-iBuChE as antigens for immunization was produced with 7.80, 2.88, 2.59, and 1.79 mg, respectively.
The affinity of each antibody against OP-iBuChE was assessed by ELISA using the sera which is gathered from mouse after second or third boosting for monoclonal antibody against OP-iBuChE. The ratio of serial dilution is 1:100, 1:1000, 1:5000, 1:10,000, 1:50,000, and 1:100,000 with 1 9 PBS. The fusion was processed when the titer of 1:1000 diluent is over 1.5 OD at 450 nm. Each anti-OPinactivated BuChE (anti-OP-iBuChE) monoclonal antibodies were evaluated for its affinity (specificity) by using different concentration of antigen and antibodies. Among them, binding affinity of the anti-soman-iBuChE monoclonal antibody was confirmed only in soman-BuChE adduct. Three of the confirmed antibodies were presented with highly OD value against antigen protein and each antibody showed for similar level of OD. For ELISA, active forms of BuChE or soman-BuChE were used to coat 96-well microplates at 100 ng/well. Each antibody was added in twofold dilution series and absorbance was measured by ELISA. The result of binding capacity of antisoman-iBuChE monoclonal antibodies for BuChE and soman-iBuChE is shown in Fig. 4 . The concentration of anti-soman-iBuChE monoclonal antibody was saturated at 500 ng/mL of concentration of BuChE and somaniBuChE, and then, soman-iBuChE was two times higher Fig. 1 Schematic representation of the cholinesterase active site of butyrylcholinesterase monomer. This figure was adapted from an image in the butyrylcholinesterase study [20] and modified by authors of this work. The average depth of BuChE gorge is 20 Å , and the average entrance radius is 2.75 Å with the maximum radius of 4.00 Å . Antibody (Ab) size is 52 Å in diameter and 150 Å in length than native BuChE for binding affinity of anti-somaniBuChE antibodies. In other words, anti-soman-iBuChE monoclonal antibody shows higher affinity to somaniBuChE than BuChE although it shows cross-reactivity.
Discussion
In conclusion, the developed anti-soman-iBuChE antibody was secreted from hybridoma cells and could be used to evaluate the intoxication of soman among OP nerve agents. As shown in Fig. 1 , the monomer of BuChE has a 20 Å deep and narrow active site gorge consisting of approximately 55 residues [20] . The OP binding site of BuChE containing Ser198 catalytic triad of esteratic site is located at the center of the subunit at the end of a deep and narrow gorge. Furthermore, Asp70 and Tyr332 residues of peripheral anionic site (PAS) at the mouth of the gorge are involved in activation control and in the initial binding of positively charged substrates such as choline esters. These two residues control the functional architecture of the BuChE active site gorge, and they have a hydrogen bond [23] . Furthermore, the average entrance radius of the BChE monomer is 2.75 Å with the maximum radius of 4.00 Å , Fig. 2 Position of Ser198 at the three-dimensional structure of BuChE that is possible to be phosphorylated by OP (A, B) . Three-dimensional structure of BuChE Ser198 phosphorylated (C) and the OP-BuChE structures for sarin-iBuChE (D), soman-iBuChE (E), VXiBuChE (F), and diazinoniBuChE (G)
which is larger than that of the AChE [24, 25] . In general, antibody (Ab) size is 52 Å in diameter, 150 Å in length. Thus, the antibody against the OP binding site of BuChE may be difficult to interact with Ser198 of BuChE. Moreover, during the development, the antibodies are attached to the B cell surface, and it may be more inaccessible to the gorge by hindrance of B cell surface antibody. In other words, the specific antibody could not get in the binding pockets of Ser198. In addition, the progressive inhibition of cholinesterase by OPs is due to phosphorylation or phosphonylation of their active site Ser198 for BuChE [26] . This specific monoclonal antibody may recognize three-dimensional structure which is changed after soman and BuChE interaction, not a binding pocket of BuChE [27, 28] , and it could be applied to detect the soman intoxication.
We have developed the first partial specific monoclonal antibody recognizing soman-BuChE complex. Comparison of anti-soman-iBuChE monoclonal antibody binding to Asp70 and to Tyr332 residues of PAS is key issues in further developing specific antibodies against such organophosphate nerve agents. In the current development of a commercial kit, we are setting up a competitive ELISA using anti-soman-iBuChE antibody that has competitive binding process to BuChE and soman-iBuChE. Taken together, our findings suggest that the use of anti-somaniBuChE antibody could distinguish between native BuChE and soman-iBuChE, and identify a person exposed to soman or suspected of the exposure cheaply, easily, and rapidly. And it is required to further develop the specific antibodies for discriminating between BuChE and OP-inactivated BuChE to further screen the intoxicated persons. Fig. 4 Comparative binding studies of anti-soman-iBuChE monoclonal antibodies to soman-iBuChE and BuChE. 100 ng/well of active forms of BuChE or soman-iBuChE was used to coat 96-well microplates. Each antibody was added with twofold dilutions and the absorbance was measured using ELISA. 1-1, 2-2, and 8-1 are clone number. All data are averages from three replicate experiments. BuChE is the closed symbol, and soman-iBuChE is the opened symbol Appl Biol Chem (2017) 60(3):233-240 239
